|
mutLBSgeneDB |
| |
| |
| |
| |
| |
| |
|
| Gene summary for CD59 |
 Gene summary |
| Basic gene Info. | Gene symbol | CD59 |
| Gene name | CD59 molecule, complement regulatory protein | |
| Synonyms | 16.3A5|1F5|EJ16|EJ30|EL32|G344|HRF-20|HRF20|MAC-IP|MACIF|MEM43|MIC11|MIN1|MIN2|MIN3|MIRL|MSK21|p18-20 | |
| Cytomap | UCSC genome browser: 11p13 | |
| Type of gene | protein-coding | |
| RefGenes | NM_000611.5, NM_001127223.1,NM_001127225.1,NM_001127226.1,NM_001127227.1, NM_203329.2,NM_203330.2,NM_203331.2, | |
| Description | 1F5 antigen20 kDa homologous restriction factorCD59 antigen p18-20 (antigen identified by monoclonal antibodies 16.3A5, EJ16, EJ30, EL32 and G344)CD59 glycoproteinLy-6-like proteinMEM43 antigenT cell-activating proteinhuman leukocyte antigen MIC11 | |
| Modification date | 20141221 | |
| dbXrefs | MIM : 107271 | |
| HGNC : HGNC | ||
| HPRD : 00117 | ||
| Protein | UniProt: P13987 go to UniProt's Cross Reference DB Table | |
| Expression | CleanEX: HS_CD59 | |
| BioGPS: 966 | ||
| Pathway | NCI Pathway Interaction Database: CD59 | |
| KEGG: CD59 | ||
| REACTOME: CD59 | ||
| Pathway Commons: CD59 | ||
| Context | iHOP: CD59 | |
| ligand binding site mutation search in PubMed: CD59 | ||
| UCL Cancer Institute: CD59 | ||
| Assigned class in mutLBSgeneDB | C: This gene just belongs to mutLBSgenes. | |
| Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
| GO ID | GO Term | PubMed ID |
| Top |
| Ligand binding site mutations for CD59 |
| Lollipop-style diagram of mutations at LBS in amino-acid sequence. We represented ligand binding site mutations only. (You can see big image via clicking.)  : non-synonymous mutation on LBS, Circle size denotes number of samples. |
 |
| Cancer type specific mutLBS sorted by frequency |
| LBS | AAchange of nsSNV | Cancer type | # samples | A41 | A41V | UCEC | 1 |
| cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
| Top |
| Protein structure related information for CD59 |
| Relative protein structure stability change (ΔΔE) using Mupro 1.1 Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
 : nsSNV at non-LBS : nsSNV at LBS |
 |
| nsSNVs sorted by the relative stability change of protein structure by each mutation Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
| LBS | AAchange of nsSNV | Relative stability change | A41 | A41V | -0.70821893 |
| (MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
| Structure image for CD59 from PDB |
| Top |
| Differential gene expression and gene-gene network for CD59 |
| Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types |
| Differential co-expressed gene network based on protein-protein interaction data (CePIN) |
| Top |
| Top |
| Phenotype information for CD59 |
| Gene level disease information (DisGeNet) |
| Disease ID | Disease name | # PubMed | Association type |
| umls:C2676767 | CD59 Deficiency | 3 | Biomarker, GeneticVariation |
| Mutation level pathogenic information (ClinVar annotation) |
| Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
| Top |
| Pharmacological information for CD59 |
| Gene expression profile of anticancer drug treated cell-lines (CCLE) Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
 |
| Drug information targeting mutLBSgene (Approved drugs only) |
| Drug status | DrugBank ID | Name | Type | Drug structure |
| Gene-centered ligand-gene interaction network |
 |
| Ligands binding to mutated ligand binding site of CD59 go to BioLip |
| Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS |
| Top |
| Conservation information for LBS of CD59 |
| Multiple alignments for P13987 in multiple species |
| LBS | AA sequence | # species | Species | A41 | ADCKTAVNCSS | 1 | Homo sapiens | A41 | SSCKINTTCSP | 1 | Mus musculus | A41 | SSCKTNSTCSP | 1 | Rattus norvegicus | N43 | CKTAVNCSSDF | 1 | Homo sapiens | N43 | CKINTTCSPNL | 1 | Mus musculus | N43 | CKTNSTCSPNL | 1 | Rattus norvegicus | Q27 | SGHSLQCYNCP | 1 | Homo sapiens | Q27 | TAVSLKCYNCL | 1 | Mus musculus | Q27 | TGVSLRCYNCL | 1 | Rattus norvegicus | V42 | DCKTAVNCSSD | 1 | Homo sapiens | V42 | SCKINTTCSPN | 1 | Mus musculus | V42 | SCKTNSTCSPN | 1 | Rattus norvegicus |
 |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |